| Date Filed | Type | Description |
| 10/05/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/29/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/27/2023 |
8-K
| Other Events Interactive Data |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/05/2023 |
4
| Charles Faith L. (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 100,000 options to buy
@ $1.14, valued at
$114k
|
|
| 07/05/2023 |
4
| Jin David (Interim PFO and COO) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 250,000 options to buy
@ $1.14, valued at
$285k
|
|
| 07/05/2023 |
4
| ROSENWALD LINDSAY A MD (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 100,000 options to buy
@ $1.14, valued at
$114k
|
|
| 07/05/2023 |
4
| KRANZLER JAY D (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 100,000 options to buy
@ $1.14, valued at
$114k
|
|
| 07/05/2023 |
4
| Oltmans Curtis Gale (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 100,000 options to buy
@ $1.14, valued at
$114k
|
|
| 07/05/2023 |
4
| Herskowitz Neil (Director) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 100,000 options to buy
@ $1.14, valued at
$114k
|
|
| 07/03/2023 |
4
| MacLean Alexandra (CEO) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 800,000 options to buy
@ $1.14, valued at
$912k
|
|
| 06/28/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Miami, FL – May 12, 2023 – Avenue Therapeutics, Inc. , a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023. “Avenue is progressing its neuro-focused clinical stage pipeline and 2023 is off to a strong start with AJ201, a first in class small molecule for the treatment of Spinal and Bulbar Muscular Atrophy , now in an ongoing Phase 1b/2a clinical trial, and BAER-101, a potentially more tolerable drug for the treatment of epilepsy and acute anxiety, advancing toward Phase 1b studies in each indication. We..." |
|
| 05/04/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
4
| Fortress Biotech, Inc. (10% Owner) has filed a Form 4 on AVENUE THERAPEUTICS, INC.|
Txns:
| Granted 52,419 shares
@ $0 |
|
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/08/2023 |
8-K
| Appointed a new director |
| 03/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 02/14/2023 |
SC 13G/A
| CVI Investments, Inc. reports a |
| 02/14/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
|